Overview |
bs-5514R-APC-Cy7 |
NFKBIA (Tyr42) Polyclonal Antibody, APC-Cy7 Conjugated |
WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat |
Cow, Sheep, Pig, Rabbit |
Specifications |
APC-Cy7 |
Rabbit |
KLH conjugated synthetic phosphopeptide derived from human IKB alpha around the phosphorylation site of Tyr42 |
Tyr42 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
4792 |
Cytoplasm, Nucleus |
NFKBIATyr42; NFKBIAphospho Y42; IKB-alphaTyr42; IKB alpha; Inhibitor of KB alpha; I kappa B alpha; IKappaBalpha; IkappaBalpha; IKBA; IKBalpha; MAD 3; MAD3; Major histocompatibility complex enhancer binding protein MAD3; NF kappa B inhibitor alpha; NFKBI; NFKBIA; Nuclear factor of kappa light chain gene enhancer in B cells; Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha. |
This gene encodes a member of the NF-kappa-B inhibitor family, which contain multiple ankrin repeat domains. The encoded protein interacts with REL dimers to inhibit NF-kappa-B/REL complexes which are involved in inflammatory responses. The encoded protein moves between the cytoplasm and the nucleus via a nuclear localization signal and CRM1-mediated nuclear export. Mutations in this gene have been found in ectodermal dysplasia anhidrotic with T-cell immunodeficiency autosomal dominant disease. [provided by RefSeq, Aug 2011]. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |